Summary
Cell lines established from advanced mammary and ovarian carcinomas were assayed for the inhibition of in vitro proliferation by various antineoplastic drugs. The assays were performed with multiple experimental cultures derived from stock cultures of the tumor cell lines in early passages of the cultivation. As determined by comparison of the 50% inhibition of in vitro growth, differential sensitivity of the individual cell lines was observed. Based on the 2-h plasma level of the drugs as discriminatory threshold between resistance and sensitivity, the in vitro effectiveness of each, drug on the individual cell lines was compared with the clinical results of chemotherapy applied to the corresponding patients. In total, positive in vitro/in vivo correlations were observed in 39 of 42 cases. The 17 cell lines evaluated retrospectively were resistant to those drugs which had been tried unsuccessfully during chemotherapy. Among the 25 cases tried prospectively 11 cases showed sensitivity in vitro and in vivo, and furthermore 11 prospective cases were resistant in vitro and in vivo.
Similar content being viewed by others
References
Abeloff MD, Effinger DS (1977) Treatment of metastatic, breast cancer with adriamycin-cyclophosphamide induction followed by alternating combination therapy. Cancer Treat Rep 61:1685–1689
Alberts DS, Chen HSG, Soehnlen B, Salmon SE, Surwit EA, Young L, Moon TE (1980) In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. Lancet II:340–342
Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA (1981) Pharmacologic studies of anticancer drugs with the human tumor stem cell assay. Cancer Chemother Pharmacol 6:253–264
Albrecht M, Simon WE, Hölzel F (1983) Testing of the, individual chemosensitivity of human mammary and ovarian carcinoma in cell culture. Proc 13th Int Congr Chemother, Vienna, Austria 224:127–129
Ali-Osman F, Maurer HR, Bier J (1983) In vitro cytostatic drug sensitivity testing in the human tumor stem cell assay: A modified method for the determination of the sensitivity index. Tumor Diagn Ther 4:1–6
Baylin SB (1982) Clonal selection and heterogeneity of human solid neoplasms. In: Fidler IJ, White RJ (eds) Design of models for testing cancer therapeutic agents. Van Nostrand Reinhold, New York, pp 50–63
Bitran JD, Desser RK, Shapiro CM, Michel A, Kozloff MF, Billings AA, Recent W (1983) Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy. Cancer 51:381–384
Bloom HJG, Richardson, WW (1957) Histological grading and prognosis in breast cancer, study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11:359–377
Brambilla C, Valagussa P, Bonadonna G (1978) Sequential combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol 1:35–39
Bruckner HW, Ratner LH, Cohen CJ, Wallach R, Kabakow B, Greenspan EM, Holland JF (1978) Combination chemotherapy for ovarian carcinoma with cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum(II) after failure of initial chemotherapy. Cancer Treat Rep 62:1021–1023
Bruckner HW, Cohen CJ, Goldberg JD, Kabakow B, Wallach RC Deppe G, Reisman AZ, Gusberg SB, Holland JF (1983) Cis-platin regimens and improved prognosis of patients with poorly differentiated ovarian cancer. Am J Obstet. Gynecol 145:653–658
Buzdar AV, Legha SS, Hortobagyi GN, Yap HY, Wiseman CL, Distefano A, Schell FC, Barnes BC, Campos LT, Blumenschein G (1981) Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47:2798–2802
Cifone MA, Fidler IJ (1981) Increasing metastatic potential is associated with increasing genetic instability of clones isolated from murine neoplasms. Proc Natl Acad Sci USA 78:6949–6952
De Lena M, Brambilla C, Morabito A, Bonadonna G (1975) Adriamycin plus vincristine compared to and combined with cyclophosphamide methotrexate, and 5-fluorouracil for advanced breast cancer. Cancer 35:1108–1115
DeVita VT, Young RC, Canellos G (1975) Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer 35:98–110
DeVita VT (1983) The relationship between tumor mass and resistance to chemotherapy. Cancer 51:1209–1220
Ehninger G, Stocker H, Wilms K (1981) Metabolisierung und Ausscheidung von Adriamycin. In: Füllenbach D, Nagel GA, Seeber S (eds) Beitr Onkol No 9. Karger, Basel, pp 16–25
Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197:893–895
Finn, C, Sadée W (1975) Determination, of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution fragmentography. Cancer Chemother Rep 59:279–286
Fleiss JL (1973) Statistical methods for rates and proportions. Wiley, New York, p 3
German J (1974) Chromosomes and cancer. Wiley, New York
Goldie JH, Coldman AJ (1979) A mathematical, model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63:1727–1733
Goldie JH, Coldman AJ, Gudauskas GA (1982) Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66:439–449
Gullo JJ, Litterst CL, McGuire PJ, Sikic BI, Hoth DF, Wolley PV (1980) Pharmacokinetics and protein binding of cis-dichlorodiammine platinum(II) administered as a one hour or as a twenty hour infusion. Cancer Chemother Pharmacol 5:21–26
Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:461–463
Harris JF, Chambers AF, Hill RP, Ling V (1982) Metastatic variants are generated spontaneously at a high rate in mouse KHT tumors. Proc Natl Acad Sci USA 79:5547–5551
Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD (1977) Assessment of response, to therapy in advanced breast cancer. Eur J Cancer 13:89–94
Henderson C (1983) Chemotherapy of breast cancer. A general overview. Cancer 51:2553–2559
Hölzel F, Albrecht M, Simon WE, Hänsel M, Metz R, Schweizer J, Dietel M (1985) Effectiveness of antineoplastic drugs on the proliferation of human mammary and ovarian carcinoma cells in monolayer, culture. J Cancer Res Clin Oncol 109:217–226
Jackson DV, Bender RA (1978) The clinical pharmacology of the vinca alcaloids, epipodophyllotoxins and maytansine. In: Pinedo HM (ed) Clinical pharmacology of antineoplastic drugs. Elsevier, Amsterdam, pp 277–293
Kern DH, Bertelsen CA, Sondak VK, Campbell MA, Worth GD, Hildebrand-Zanki SU, Morton DL, Storm FK (1983) Development of techniques to improve, the growth rate, precision, and accuracy for chemosensitivity assays: Implications, for predictive drug testing. Proc 13th Int Congr Chemother, Vienna, Austria 224:17–22
Levy G (1973) Relationship between pharmacological effects and plasma or tissue concentration of drugs in man. In: Davies DS, Prickard BNC (eds) Biological effects of drugs in relation to their plasma or tissue concentrations in man. University Park Press, Baltimore, pp 83–95
Loeb LA, Springate CF, Battula N (1974) Errors in DNA replication as a basis of malignant changes. Cancer Res 34:2311–2321
Lyss AP, Loeb UV (1984) Chemotherapy, of advanced breast cancer. A general survey. Cancer 53:778–782
Matthiessen H von, Feldhammer B, Schürmann B, Koldovsky U (1984) Klinische Bedeutung des Kurzzeitinkubationstests, für die Therapie des metastasierten Mammakarzinoms. Dtsch Med Wochenschr 109:1356–1361
Moon TE (1980) Quantitative and statistical analysis of the association between in vitro and in vivo studies. In: Salmon SE (ed) Cloning of human tumor stem cells. Alan R Liss, New York, pp 209–221
Notari RE (1975) Principles of pharmacokinetics. In: Biopharmaceutics and pharmacokinetics. Dekker, New York, pp 43–100
Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28
Ozols RF, Garvin AJ, Costa J, Simon RM, Young RC (1980) Advanced ovarian cancer. Correlation of histological grade with response to therapy and survival. Cancer, 45:572–581
Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283:139–146
Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE (1978) Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321–1327
Salmon SE (1983) In vitro phase II trials with the human tumor clonogenic assay. Proc 13th Int Congr Chemother, Vienna, Austria 224:43–48
Scarff RW, Torloni H (1968) Histological typing of breast tumours. International histological classification of tumours. No 2. World Health Organization, Geneva
Scully RE (1977) Ovarian tumors. Am J Pathol 87:686–720
Serov SF, Scully RE, Sobin LH (1973) Histological typing of ovarian tumours. International histological classification of tumours. No 9. World Health Organization, Geneva
Simon WE, Hölzel F (1979) Hormone sensitivity of gynecological tumor cells in tissue culture. J Cancer Res Clin Oncol 94:307–323
Simon WE, Albrecht M, Hänsel M, Dietel M, Hölzel (1983a) Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones. J Natl Cancer Inst 70:839–845
Simon WE, Hölzel F, Albrecht M (1983b) Hormonal requirements of in vitro growth in human mammary and ovarian carcinoma cell cultures. In: Fischer G, Wieser RJ (eds) Hormonally defined media: a tool in cell biology. Springer Berlin, pp 446–448
Simon WE, Hänsel M, Dietel M, Matthiesen L, Albrecht M, Hölzel F (1984a) Alteration of steroid hormone sensitivity during the cultivation of human mammary carcinoma cells. In Vitro 20:157–166
Simon WE, Albrecht M, Trams G, Dietel M, Hölzel F (1984b) In vitro growth promotion of human mammary carcinoma cells by steroid hormones tamoxifen and prolactin. J Natl Cancer Inst 73:313–321
Surwit EA, Alberts DS, Crisp W, Jackson RA, Grozea PN, Leigh S (1983) Multiagent chemotherapy in relapsing ovarian cancer. Am J Obstet Gynecol 146:613–616
Tormey DC, Gehnan R, Band PR, Sears M, Rosenthal SN, De Wys W, Perlia C, Rice MA (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50:1235–1244
Vogl SE, Pagano M, Kaplan BH, Greenwald E, Arseman J, Bennett B (1983) Cis-platin based combination chemotherapy for advanced ovarian cancer. Cancer 51:2024–2030
Volm M (1981) In vitro short-term test to determine the resistance of human tumors to chemotherapy. Cancer 48:2127–2135
Von Hoff DD, Casper J, Bradley, E, Sandbach J, Jones D, Makuch R (1981) Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70:1027–1032
Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT, Casper JT, Mattox DE, Page CP, Cruz AB, Sandbach JF (1983) Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926–1931
Wagner TH, Heydrich D, Volker G, Hohorst HJ (1980) Über Blutspiegel und Urin-Ausscheidung von aktiviertem Cyclophosphamid und seinen Deaktivierungsprodukten beim Menschen. J Cancer Res Clin Oncol 96:79–94
Welander CE, Homesley HD, Jobson VW (1983) In vitro chemotherapy testing of gynecological tumors: Basis for planning therapy?. Am J Obstet Gynecol 147:188–193
Williams TJ, Lieber MM, Podratz KC, Malkasian GD (1983) Soft agar colony formation assay for in vitro testing of sensitivity to chemotherapy of gynecologic malignancies Am J Obstet Gynecol 145:940–945
Wiltshaw E, Sebramarin S, Alexopoulos C, Barker GH (1979) Cancer, of the ovary: A summary of experience with cis-dichlorodiammineplatinum(II) at the Royal Marsden Hospital. Cancer Treat Rep 63:1545–1548
Yunis JJ (1983) The chromosomal basis of human neoplasia. Science 221:227–236
Zurek WZ, Ojima Y, Anderson LL, Collins GJ, Oberfield RA, Sullivan RD (1968) Pharmacologic studies of methotrexate in man. Surg Gynecol Obstet 126:331–338
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Albrecht, M., Simon, W.E. & Hölzel, F. Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy. J Cancer Res Clin Oncol 109, 210–216 (1985). https://doi.org/10.1007/BF00390360
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00390360